Tobevibart

DB18986InvestigationalProtein Based Therapies

Tobevibart is under investigation in clinical trial NCT05612581 (A Platform Study to Evaluate Investigational Therapies in Chronic Hepatitis B Infection).

Mechanism: Pharmacologically active on HBsAg
Curator reviewed
Also known as: Immunoglobulin G1 [238-alanine,332-leucine,334-glutamic acid,430-leucine,436-serine], anti-(hepatitis B virus surface antigen) (human monoclonal VIR-3434 γ1-chain), disulfide with human monoclonal VIR-3434 λ-chain, dimer
Code names: VIR-3434

Resolves to

Compound

UNIIPL93ZHC4L3CAS2645440-65-7

Targets

Q69600S gene

What you can answer from here — as of July 09, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

9Clinical trialsPhase, status and sponsor resolved per trial

5+ReferencesStructured and connected to the statements they support

Which drugs share a target with Tobevibart, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account